Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Serina Therapeutics, Inc. (SER)
USD1.95
-0.14 (-6.70%)
US AMEX Healthcare Biotechnology
Address
601 Genome Way 35806
Huntsville, AL, US
Huntsville, AL, US
CEO
Steven A. Ledger
Website
serinatherapeutics.com
IPO
2000-01-21
CIK 1708599 ISIN US81751A1088
Also trades on
New York Stock Exchange American · SER (USD)
New York Stock Exchange Arca · AGE (USD)
Description
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
News Sentiment (7d)
4 articles
- Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease Globe News Wire
- Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study MarketBeat
- Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.95
-0.14 (-6.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
109.6K
Beta
0.03
Float Shares
3.31M
Free Float %
33.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.65% | -4.09% | -20.00% | -0.61% | -57.07% | -14.14% | -69.80% | -91.30% | -96.14% | -98.31% | -98.31% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.95
DCF (Unlevered)
0.10
-94.7%
DCF (Levered)
0.28
-85.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-4.17
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-26.5% Q1'26: -18.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +372.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+38.5% Q1'26: +23.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
56.0K
est: 100.0K (-44.0%)
|
—
est: 130.0K (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-10.49M
est: -7.1K (-147,833.4%)
|
-18.91M
est: -9.2K (-205,097.5%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-10.68M
est: -7.3K (-146,576.7%)
|
-18.98M
est: -9.5K (-200,428.2%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-11.14M
est: 2.45M (-555.6%)
|
-19.18M
est: -21.20M (+9.5%)
|
-14.37M
-14.37M – -14.37M
+32.2% YoY
|
-10.70M
-10.70M – -10.70M
+25.5% YoY
|
-9.17M
-9.17M – -9.17M
+14.3% YoY
|
-12.13M
-12.13M – -12.13M
-32.2% YoY
|
-13.76M
-13.76M – -13.76M
-13.4% YoY
|
| SGA |
9.43M
est: 3.47M (+171.6%)
|
11.00M
est: 4.51M (+143.7%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.51
est: 0.24 (-729.2%)
|
-1.91
est: -2.08 (+8.2%)
|
-1.41
-1.41 – -1.41
+32.2% YoY
|
-1.05
-1.05 – -1.05
+25.5% YoY
|
-0.90
-0.90 – -0.90
+14.3% YoY
|
-1.19
-1.19 – -1.19
-32.2% YoY
|
-1.35
-1.35 – -1.35
-13.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.25M
OE per share TTM
-1.72
Owner's Yield
-92.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
48.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
589.5K
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Juvenescence Limited | 55.54M | 72.10% | 55.54M | — | 55.54M | — | CO | Isle of Man | 2022-08-23 | ↗ |
| 2 | Neal C. Bradsher | 3.00M | 8.40% | 6.3K | 3.00M | 6.3K | 3.00M | HC, IN | Delaware | 2018-12-10 | ↗ |
| 3 | Broadwood Capital, Inc. | 3.00M | 8.40% | — | 3.00M | — | 3.00M | IA, CO | Delaware | 2018-12-10 | ↗ |
| 4 | Broadwood Partners, L.P. | 3.00M | 8.40% | — | 3.00M | — | 3.00M | PN | Delaware | 2018-12-10 | ↗ |
| 5 | David A. Taft | 2.66M | 7.24% | — | 2.66M | — | — | IN | States of America | 2019-02-14 | ↗ |
| 6 | IBS Capital LLC | 2.66M | 7.24% | — | 2.66M | — | — | IA | Massachusetts | 2019-02-14 | ↗ |
| 7 | The IBS Turnaround Fund (QP) (A Limited Partnership) | 1.67M | 4.59% | — | 1.67M | — | — | PN | Massachusetts | 2019-02-14 | ↗ |
| 8 | The IBS Turnaround Fund, L.P. | 815.4K | 2.26% | — | 815.4K | — | — | PN | Massachusetts | 2019-02-14 | ↗ |
| 9 | Moreadith | 615.0K | 6.80% | 615.0K | — | 615.0K | — | IN | States | 2024-04-03 | ↗ |
| 10 | The IBS Opportunity Fund, Ltd. | 176.3K | 0.49% | — | 176.3K | — | — | FI | of The Bahamas | 2019-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-8 vs prev Q
New positions
7
Closed positions
15
Increased
9
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 180.0K +— (+0.0%) | 344.4K -620.5K (-64.3%) | 1.74% -0.058 pp | 0.00% +0.000 pp | USD6.63 -71.2% | 8 qtrs — |
| 2 | WAVERLY ADVISORS, LLC | 67.5K +— (+0.0%) | 129.1K -232.6K (-64.3%) | 0.65% -0.022 pp | 0.00% -0.003 pp | USD7.38 -74.1% | 7 qtrs — |
| 3 | BROADWOOD CAPITAL INC | 54.5K -28.7K (-34.5%) | 104.2K -341.7K (-76.6%) | 0.53% -0.305 pp | 0.01% -0.021 pp | USD11.83 -83.9% | 8 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 30.4K +801.0 (+2.7%) | 58.2K -100.5K (-63.3%) | 0.29% -0.002 pp | 0.00% +0.000 pp | USD7.79 -75.5% | 7 qtrs — |
| 5 | LINSCOMB & WILLIAMS, INC. | 18.8K +— (+0.0%) | 36.0K -64.8K (-64.3%) | 0.18% -0.006 pp | 0.00% -0.003 pp | USD5.36 -64.4% | 2 qtrs — |
| 6 | KEEL POINT, LLC | 17.8K +— (+0.0%) | 34.0K -61.3K (-64.3%) | 0.17% -0.006 pp | 0.00% -0.004 pp | USD6.69 -71.4% | 6 qtrs — |
| 7 | BLACKROCK, INC. | 17.2K +4.1K (+31.5%) | 33.0K -37.3K (-53.1%) | 0.17% +0.036 pp | 0.00% +0.000 pp | USD5.17 -63.1% | 6 qtrs — |
| 8 | NORTHERN TRUST CORP | 14.1K -455.0 (-3.1%) | 26.9K -51.0K (-65.4%) | 0.14% -0.009 pp | 0.00% +0.000 pp | USD6.56 -70.9% | 6 qtrs — |
| 9 | STATE STREET CORP | 12.8K +— (+0.0%) | 24.4K -44.0K (-64.3%) | 0.12% -0.004 pp | 0.00% +0.000 pp | USD5.36 -64.4% | 2 qtrs — |
| 10 | HIGHTOWER ADVISORS, LLC | 12.0K -6.2K (-34.2%) | 22.9K -74.7K (-76.5%) | 0.12% -0.066 pp | 0.00% 0.000 pp | USD8.63 -77.9% | 7 qtrs — |
| 11 | WELLS FARGO & COMPANY/MN | 3.6K +3.6K (+180,100.0%) | 6.9K +6.9K (+62,572.7%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD1.92 -0.5% | 8 qtrs — |
| 12 | TOWER RESEARCH CAPITAL LLC (TRC) | 449.00 +286.0 (+175.5%) | 859.00 -15.0 (-1.7%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD3.16 -39.6% | 8 qtrs — |
| 13 | UBS GROUP AG | 433.00 -3.0K (-87.5%) | 829.00 -17.7K (-95.5%) | 0.00% -0.031 pp | 0.00% +0.000 pp | USD5.36 -64.4% | 8 qtrs — |
| 14 | PISCATAQUA SAVINGS BANK | 28.00 +— (+0.0%) | 53.00 -97.0 (-64.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD8.68 -78.0% | 7 qtrs — |
| 15 | PACIFICA PARTNERS INC. | 8.00 +— (+0.0%) | 17.00 -24.0 (-58.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.63 -77.9% | 7 qtrs — |
| 16 | ALBION FINANCIAL GROUP /UT | 8.00 +— (+0.0%) | 16.00 -27.0 (-62.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.75 -83.7% | 8 qtrs — |
| 17 | MORGAN STANLEY | 8.00 +— (+0.0%) | 15.00 -28.0 (-65.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.13 -79.1% | 8 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 3.00 -212.0 (-98.6%) | 6.00 -1.1K (-99.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD5.67 -66.3% | 7 qtrs — |
| 19 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 2.00 +— (+0.0%) | 4.00 -7.0 (-63.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.00 -61.8% | 2 qtrs — |
| 20 | BNP PARIBAS ARBITRAGE, SNC | 2.00 +— (+0.0%) | 4.00 -7.0 (-63.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.50 -83.4% | 8 qtrs — |
| 21 | ADVISOR GROUP HOLDINGS, INC. | 2.00 -9.0 (-81.8%) | 2.00 -52.0 (-96.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD7.50 -74.5% | 8 qtrs — |
| 22 | GLOBAL RETIREMENT PARTNERS, LLC | 1.00 +— (+0.0%) | 2.00 -3.0 (-60.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD6.00 -68.2% | 3 qtrs — |
| 23 | CITIGROUP INC | — -2.3K (-100.0%) | — -12.5K (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 24 | ADVISORY SERVICES NETWORK, LLC | — -14.0 (-100.0%) | — -75.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 25 | JPMORGAN CHASE & CO | — -10.0 (-100.0%) | — -54.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 59.9K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 490.53 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 1.3K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 99.48 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 230.2K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 504.41 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 274.55 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 110.78 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 12.24 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.73 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.65
Neutral
Ratio by volume
3.00
Bullish
Buys
13
Sells
20
Shares acquired
542.6K
Shares disposed
169.0K
Cash buys
—
Cash sales
10.00
Net activity
+373,600
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Venkatesan Jay | Director | A-Award | A | Common Stock | 7,553 | 1.94 | 14.7K | 7,553 | D | ↗ |
| 2026-03-31 | Bailey Gregory | Director | A-Award | A | Common Stock | 59,667 | 1.94 | 115.8K | 126,910 | D | ↗ |
| 2026-03-23 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 267,686 | D | ↗ |
| 2026-03-19 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 39,000 | 0.06 | 2.3K | 274,186 | D | ↗ |
| 2026-02-03 | Tenjarla Srini | Officer | A-Award | A | Stock Option (right to buy) | 69,000 | 2.76 | 190.4K | 69,000 | D | ↗ |
| 2026-02-03 | Moreadith Randall | Officer | A-Award | A | Stock Option (right to buy) | 69,000 | 2.76 | 190.4K | 69,000 | D | ↗ |
| 2026-02-03 | LEDGER STEVEN A | Director / Officer | A-Award | A | Stock Option (right to buy) | 230,100 | 2.76 | 635.1K | 230,100 | D | ↗ |
| 2026-02-03 | GILL SIMBA | Director | A-Award | A | Stock Option (right to buy) | 92,000 | 2.76 | 253.9K | 92,000 | D | ↗ |
| 2026-02-02 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 313,186 | D | ↗ |
| 2026-01-28 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 319,686 | D | ↗ |
| 2026-01-22 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 2,500 | 0.06 | 150.00 | 326,186 | D | ↗ |
| 2026-01-21 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 2,000 | 0.06 | 120.00 | 328,686 | D | ↗ |
| 2026-01-20 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 2,000 | 0.06 | 120.00 | 330,686 | D | ↗ |
| 2026-01-14 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 1,084 | 0.06 | 65.04 | 332,686 | D | ↗ |
| 2026-01-13 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,416 | 0.06 | 324.96 | 333,770 | D | ↗ |
| 2026-01-08 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 13,000 | 0.06 | 780.00 | 13,000 | D | ↗ |
| 2025-12-23 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 4,100 | 0.06 | 246.00 | 4,100 | D | ↗ |
| 2025-12-22 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,673 | 0.06 | 340.38 | 356,286 | D | ↗ |
| 2025-12-16 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 3,227 | 0.06 | 193.62 | 361,959 | D | ↗ |
| 2025-12-12 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 1,700 | 0.06 | 102.00 | 1,700 | D | ↗ |
| 2025-12-11 | Moreadith Randall | Officer | S-Sale | D | Common Stock | 3,555 | 3.24 | 11.5K | 0 | D | ↗ |
| 2025-12-10 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 645 | 0.06 | 38.70 | 370,441 | D | ↗ |
| 2025-12-09 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 600 | 0.06 | 36.00 | 371,086 | D | ↗ |
| 2025-12-03 | Moreadith Randall | Officer | S-Sale | D | Common Stock | 5,000 | 3.52 | 17.6K | 0 | D | ↗ |
| 2025-12-02 | Moreadith Randall | Officer | S-Sale | D | Common Stock | 1,500 | 3.91 | 5.9K | 0 | D | ↗ |
| 2025-11-25 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,965 | 0.06 | 357.90 | 378,186 | D | ↗ |
| 2025-11-24 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 535 | 0.06 | 32.10 | 384,151 | D | ↗ |
| 2025-11-18 | Moreadith Randall | Officer | S-Sale | D | Common Stock | 6,500 | 3.75 | 24.4K | 0 | D | ↗ |
| 2025-11-10 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 6,500 | 0.06 | 390.00 | 6,500 | D | ↗ |
| 2025-11-07 | WILSON KAREN J | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 3.91 | 39.1K | 10,000 | D | ↗ |
| 2025-11-07 | Venkatesan Jay | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 3.91 | 39.1K | 10,000 | D | ↗ |
| 2025-11-07 | Marshall Richard Peter | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 3.91 | 39.1K | 10,000 | D | ↗ |
| 2025-11-07 | Brannan Stephen K. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 3.91 | 39.1K | 10,000 | D | ↗ |
| 2025-11-07 | Bailey Gregory | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 3.91 | 39.1K | 10,000 | D | ↗ |
| 2025-11-05 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 3,398 | 0.06 | 203.88 | 397,686 | D | ↗ |
| 2025-11-04 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 3,102 | 0.06 | 186.12 | 3,102 | D | ↗ |
| 2025-10-28 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,551 | 0.06 | 333.06 | 404,186 | D | ↗ |
| 2025-10-27 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 949 | 0.06 | 56.94 | 409,737 | D | ↗ |
| 2025-10-20 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 6,500 | 0.06 | 390.00 | 6,500 | D | ↗ |
| 2025-10-13 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 4,326 | 0.06 | 259.56 | 4,326 | D | ↗ |
| 2025-08-26 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 45,632 | 0.06 | 2.7K | 421,512 | D | ↗ |
| 2025-08-25 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 2,042 | 0.06 | 122.52 | 2,042 | D | ↗ |
| 2025-08-20 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 2,077 | 0.06 | 124.62 | 2,077 | D | ↗ |
| 2025-08-18 | Moreadith Randall | Officer | S-Sale | D | Common Stock | 2,227 | 5.25 | 11.7K | 0 | D | ↗ |
| 2025-08-12 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,500 | 0.06 | 330.00 | 473,490 | D | ↗ |
| 2025-08-04 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 5,500 | 0.06 | 330.00 | 478,990 | D | ↗ |
| 2025-07-29 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 4,196 | 0.06 | 251.76 | 484,490 | D | ↗ |
| 2025-07-28 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 6,500 | 0.06 | 390.00 | 6,500 | D | ↗ |
| 2025-07-21 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 495,186 | D | ↗ |
| 2025-07-14 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 501,686 | D | ↗ |
| 2025-07-07 | Moreadith Randall | Officer | M-Exempt | D | Stock Option (right to buy) | 6,500 | 0.06 | 390.00 | 508,186 | D | ↗ |
| 2025-06-30 | Moreadith Randall | Officer | M-Exempt | A | Common Stock | 6,500 | 0.06 | 390.00 | 6,500 | D | ↗ |
| 2025-05-22 | Brannan Stephen K. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 5.89 | 235.6K | 40,000 | D | ↗ |
| 2025-04-08 | Venkatesan Jay | Director | A-Award | A | Series A Convertible Preferred Stock | 96,525 | 5.18 | 500.0K | 96,525 | I | ↗ |
| 2025-04-08 | Bailey Gregory | Director | A-Award | A | Series A Convertible Preferred Stock | 762,548 | 5.18 | 3.95M | 762,548 | D | ↗ |
| 2025-03-28 | LEDGER STEVEN A | Director / Officer | J-Other | A | Common Stock | 95,730 | 0.00 | — | 95,730 | D | ↗ |
| 2025-02-12 | Venkatesan Jay | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 4.60 | 184.0K | 40,000 | D | ↗ |
| 2025-01-31 | Juvenescence Ltd | 10% Owner | A-Award | A | Warrants | 377,864 | 18.00 | 6.80M | 755,728 | I | ↗ |
| 2025-01-14 | WILSON KAREN J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-17 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 3,866 | 4.59 | 17.7K | 67,243 | D | ↗ |
| 2024-11-27 | Juvenescence Ltd | 10% Owner | A-Award | A | Warrants | 377,864 | 18.00 | 6.80M | 377,864 | I | ↗ |
| 2024-09-20 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 1,137 | 6.03 | 6.9K | 63,377 | D | ↗ |
| 2024-09-19 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 11,679 | 6.11 | 71.4K | 62,240 | D | ↗ |
| 2024-09-18 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 2,709 | 6.23 | 16.9K | 50,561 | D | ↗ |
| 2024-09-12 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 6,000 | 6.47 | 38.8K | 17,443 | — | ↗ |
| 2024-09-09 | LEDGER STEVEN A | Director / Officer | A-Award | A | Stock Option (right to buy) | 376,388 | 7.40 | 2.79M | 490,350 | — | ↗ |
| 2024-08-20 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 1,776 | 8.25 | 14.7K | 47,582 | — | ↗ |
| 2024-08-19 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 6,400 | 7.93 | 50.8K | 45,806 | — | ↗ |
| 2024-08-16 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 6,400 | 7.31 | 46.8K | 39,406 | — | ↗ |
| 2024-08-15 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 1,800 | 6.59 | 11.9K | 3,040 | — | ↗ |
| 2024-08-15 | CURHAN GREGORY S | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 6.66 | 1.67M | 250,000 | — | ↗ |
| 2024-08-15 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 6,400 | 6.65 | 42.6K | 33,006 | — | ↗ |
| 2024-08-14 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 6,400 | 7.07 | 45.2K | 26,606 | — | ↗ |
| 2024-07-15 | Tenjarla Srini | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 9.50 | 1.76M | 185,000 | — | ↗ |
| 2024-06-25 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 2,600 | 9.00 | 23.4K | 10,907 | — | ↗ |
| 2024-06-21 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 5,000 | 9.50 | 47.5K | 8,307 | — | ↗ |
| 2024-06-06 | Juvenescence Ltd | 10% Owner | M-Exempt | D | Warrants | 377,865 | 13.20 | 4.99M | 755,728 | I | ↗ |
| 2024-05-30 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 5,205 | 9.50 | 49.4K | 20,206 | — | ↗ |
| 2024-05-29 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 1,173 | 9.50 | 11.1K | 15,001 | — | ↗ |
| 2024-05-28 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 9,019 | 9.50 | 85.7K | 13,828 | — | ↗ |
| 2024-05-23 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 2,371 | 9.50 | 22.5K | 4,809 | — | ↗ |
| 2024-05-21 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 2,500 | 9.75 | 24.4K | 9,900 | — | ↗ |
| 2024-05-21 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 1,422 | 9.50 | 13.5K | 1,522 | — | ↗ |
| 2024-05-20 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 1,240 | 9.44 | 11.7K | 1,240 | — | ↗ |
| 2024-05-20 | Bailey Gregory | Director | P-Purchase | A | Common Stock | 100 | 9.00 | 900.00 | 100 | — | ↗ |
| 2024-05-17 | MINTZ STEVEN | Director | P-Purchase | A | Common Stock | 554 | 8.50 | 4.7K | 554 | — | ↗ |
| 2024-04-15 | GILL SIMBA | Director | A-Award | A | Stock Option (right to buy) | 295,300 | 11.01 | 3.25M | 295,300 | — | ↗ |
| 2024-04-12 | GILL SIMBA | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-01 | Marshall Richard Peter | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.83 | 473.1K | 40,000 | — | ↗ |
| 2024-04-01 | MINTZ STEVEN | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.83 | 473.1K | 41,812 | — | ↗ |
| 2024-04-01 | HARRIS J MILTON | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.83 | 473.1K | 110,332 | — | ↗ |
| 2024-04-01 | Gross Remy | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.83 | 473.1K | 157,219 | — | ↗ |
| 2024-04-01 | Bailey Gregory | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 11.83 | 473.1K | 44,691 | — | ↗ |
| 2024-03-26 | Viegas Tacey | Officer | — | D | Stock Option (right to buy) | 138,326 | 0.06 | 8.3K | 0 | — | ↗ |
| 2024-03-26 | Moreadith Randall | Officer | — | D | Stock Option (right to buy) | 93,775 | 0.06 | 5.6K | 0 | — | ↗ |
| 2024-03-26 | Marshall Richard Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-26 | LEDGER STEVEN A | Director / Officer | — | D | Stock Option (right to buy) | 113,962 | 0.06 | 6.8K | 0 | — | ↗ |
| 2024-03-26 | HARRIS J MILTON | Director | — | D | Stock Option (right to buy) | 35,166 | 0.06 | 2.1K | 0 | — | ↗ |
| 2024-03-26 | Gross Remy | Director | — | D | Stock Option (right to buy) | 48,841 | 0.06 | 2.9K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
10.00M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Steve Ledger Chief Executive Officer | 450.0K | 187.5K | — | — | — | — | 637.5K | 0.00% | ↗ |
| 2 | 2025 | Randall Moreadith, M.D., Ph.D. Chief Development Officer | 425.0K | 138.2K | — | — | — | — | 563.2K | 0.00% | ↗ |
| 3 | 2025 | Srini Tenjarla, Ph.D. Chief Technical Operations Officer | 375.0K | 152.4K | — | — | — | — | 527.4K | 0.00% | ↗ |
| 4 | 2024 | Steve Ledger Chief Executive Officer | 326.3K | 144.9K | — | 3.23M | — | — | 3.70M | 87.28% | ↗ |
| 5 | 2024 | Srini Tenjarla, Ph.D. Chief Technical Operations Officer | 171.9K | 89.5K | — | 1.52M | — | — | 1.78M | 85.33% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steven A. Ledger | Chief Executive Officer & Director | 637.5K | male |
| Randall W. Moreadith | Chief Development Officer | 563.2K | — |
| Srini Tenjarla | Chief Technical Operations Officer | 527.4K | — |
| Balkrishan Gill | Executive Co-Chairman of the Board | 300.0K | — |
| Gregory S. Curhan | Chief Financial Officer | 252.7K | male |
| J. Milton Harris | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board | 53.1K | — |
| Joshua Thomas | Head of Chemistry | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SER
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
